Revance Therapeutics traded at $22.15 this Friday December 2nd, increasing $0.39 or 1.79 percent since the previous trading session. Looking back, over the last four weeks, Revance Therapeutics gained 2.98 percent. Over the last 12 months, its price rose by 51.71 percent. Looking ahead, we forecast Revance Therapeutics to be priced at 22.26 by the end of this quarter and at 20.14 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
22.15
Daily Change
1.79%
Yearly
51.71%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
AbbVie 163.66 2.03 1.26% 37.70%
ALKERMES 26.09 0.89 3.53% 18.38%
Bristol-Myers Squibb 81.10 0.25 0.31% 44.00%
Cara Therapeutics 12.77 0.81 6.77% 3.74%
Coherus Biosciences 6.93 0.24 3.59% -60.96%
Endo International 0.09 0.001 1.28% -98.10%
Horizon Pharma 104.85 3.97 3.94% 5.02%
Jazz Pharmaceuticals 157.25 0.71 0.45% 30.76%
J&J 178.88 0.14 0.08% 12.23%
Eli Lilly 374.76 4.43 1.20% 52.60%
Merck & Co 110.04 0.24 0.22% 50.04%
Neurocrine Biosciences 126.81 0.50 0.40% 59.15%
Pacira 47.25 0.02 0.04% -10.05%
P&G 150.61 1.36 0.91% 0.49%
Revance Therapeutics 22.15 0.39 1.79% 51.71%
Supernus Pharmaceuticals 37.51 0.49 1.32% 23.43%
Teva Pharmaceutical Industries 8.66 -0.04 -0.46% 7.58%

Indexes Price Day Year
USND 11461 -20.95 -0.18% -24.02%
US2000 1893 11.16 0.59% -12.34%

Revance Therapeutics
Revance Therapeutics, Inc. is a biotechnology company that is focused on aesthetic and therapeutic offerings, including neuromodulator product, DaxibotulinumtoxinA for Injection. The DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with purified botulinum toxin that does not contain human or animal-based components. The Company is also evaluating DaxibotulinumtoxinA for Injection in the full upper face, including glabellar lines, forehead lines, and crow’s feet, as well as in two therapeutic indications cervical dystonia and adult upper limb spasticity. It offers products and services for United States aesthetics practices, including the resilient hyaluronic acid (RHA) Collection of dermal fillers and HintMD fintech platform. The RHA Collection of dermal fillers is a filler for the correction of dynamic facial wrinkles and folds. HintMD fintech platform includes integrated smart payment, subscription, and loyalty digital services.